We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Study Reveals Varying Antibody Responses and Adverse Reactions Among Recipients of Different COVID-19 Vaccines

By HospiMedica International staff writers
Posted on 29 Sep 2021
Print article
Illustration
Illustration

A new study revealing how antibodies against the SARS-CoV-2 virus can vary among recipients of different COVID-19 vaccines was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

The study by researchers at the Dartmouth-Hitchcock Medical Center (Lebanon, NH, USA) shows how antibody responses and adverse reactions can differ in recipients of the Moderna and Pfizer COVID-19 vaccines.

Vaccines have become essential tools in the fight against COVID-19, but it’s still unclear exactly how the antibodies generated from different vaccines change or wane over time. Meanwhile, the spread of the Delta variant and the rising number of breakthrough infections have both highlighted the importance of characterizing antibodies against SARS-CoV-2 in both vaccinated and unvaccinated individuals. Knowing more about antibody patterns could also help clinicians assess individuals’ immunity to SARS-CoV-2, in addition to helping with the diagnosis and management of patients.

In the new study, the researchers collected blood samples of 78 individuals who received the Moderna vaccine and 70 individuals who received the Pfizer vaccine, before the second vaccine dose, 14 days after the second dose, and 30 days after. The study participants also took a survey where they rated the severity of adverse effects and symptoms after vaccination. Overall, individuals who received the Moderna vaccine showed a higher antibody response against the viral spike protein compared with those who received the Pfizer vaccine (4,244 U/mL vs. 1,986 U/mL 30 days after dose two) and also reported stronger side effects. However, the researchers have cautioned that these differences could arise from confounding variables such as the higher mRNA dosage in the Moderna vaccine. The team also found that antibody responses had dropped 30 days after the second dose, regardless of the vaccine given.

“We can’t claim Moderna is better than Pfizer based on these results … but it does seem there is more of a response from Moderna at least in terms of the assay that we used,” said Michael Kelliher, PhD, of Dartmouth-Hitchcock Medical Center, who led the research. “How that correlates with the total adaptive immune response is unknown, and there’s still a decent amount of research that needs to be done on this topic.”

Related Links:
Dartmouth-Hitchcock Medical Center

Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Ventilator
TRventi-3D

Print article
ADLM

Channels

Critical Care

view channel
Image: AI could help physicians detect abnormal heart rhythms earlier (Photo courtesy of 123RF)

AI to Improved Diagnosis of Atrial Fibrillation

Abnormal heart rhythms frequently arise from—and contribute to—structural abnormalities in the heart. Atrial fibrillation is a specific type of abnormal rhythm that may not be consistently present, often... Read more

Surgical Techniques

view channel
Image: ‘Wraparound’ implants represent a new approach to treating spinal cord injuries (Photo courtesy of 123RF)

Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries

The spinal cord functions as a vital conduit, transmitting nerve impulses to and from the brain, much like a highway. When the spinal cord is damaged, this flow of information is disrupted, leading to... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more